Retinal Age Model Tied to Disease Risk

• by Andrea Surnit

• May 1, 2026

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

• by Andrea Surnit

• July 20, 2026

• 3 min

Editorial: Dynamics of endocrine system dysfunctions and neuro-ophthalmic manifestations: early diagnostic to therapeutic implications

• by Kumar, Dhiraj , Naqvi, Ahmad Abu Turab , Gupta, Rohan , Kumari, Smita , Waseem, Rashid , Hassan, Md. Imtaiyaz

• May 31, 2026

Is dry skin a clue to diabetic retinopathy? Clinical insights from the overall dry skin score

• by Özge Özer, Dilek Menteşoğlu, Göknur Yorulmaz

• June 17, 2026